Clinical trial / 2017
Chlorella vulgaris supplementation affected weight and glucose changes in fatty liver disease
Seventy patients with non-alcoholic fatty liver disease were randomized to receive 1,200 mg daily of Chlorella vulgaris or placebo for 8 weeks. Weight reduction was significantly greater in the supplemented arm compared to placebo. Between-group differences in mean changes were significant for serum glucose and TNF-α after adjusting for baseline values and insulin (reported adjusted P-values: 0.014, 0.005, 0.014), but not for other measured outcomes.
- Study type
- Randomized double-blind placebo-controlled trial
- Who was studied
- 70 patients with non-alcoholic fatty liver disease
- What was measured
- Anthropometric measures, liver enzymes, glucose homeostasis, and inflammatory markers
THE PAPER
Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial.
Ebrahimi-Mameghani M, Sadeghi Z, Abbasalizad Farhangi M, Vaghef-Mehrabany E, Aliashrafi S. Clin Nutr, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.